LOGIN 

 

JOIN

 

RENEW

2020 Press Releases

HomeAboutNewsroomPress ReleasesPress Releases from the ATS2020 Press Releases ▶ Boehringer Ingelheim Pharmaceuticals, Inc., Makes $500,000 Donation to Support COVID-19 Related Activities by American Thoracic Society
Boehringer Ingelheim Pharmaceuticals, Inc., Makes $500,000 Donation to Support COVID-19 Related Activities by American Thoracic Society

New York, NY – April 07, 2020 – Today, the American Thoracic Society announced that Boehringer Ingelheim Pharmaceuticals, Inc., donated $500,000 to support the ATS COVID-19 Crisis Fund, a newly launched initiative to develop and disseminate research, education and scientific recommendations to providers in the pulmonary and critical care communities, as well as other clinicians in need of expanding their skill set during this emergency. Boehringer Ingelheim is the first to make a donation to the Fund.

The COVID-19 pandemic has posed significant challenges for pulmonary and critical care specialists worldwide. As a membership society of health care professionals committed to improving lung health, the American Thoracic Society is a leading voice in the discourse on initiatives to counter the spread of the coronavirus and provide support to those on the frontlines treating those who are sick. In order to fulfill its mission to the greatest extent possible as COVID-19 ravages individuals and medical infrastructures worldwide, ATS is seeking industry support.

“On behalf of the entire ATS community I want to thank Boehringer Ingelheim for their incredibly generous support,” said ATS President James Beck, MD. “Everyone in the respiratory community – health care providers at all levels, government and industry – are working shoulder to shoulder to manage the incredible challenges surrounding the COVID-19 pandemic. This gift will go a long way in helping the ATS pursue its mission of enhancing patient care at a time when resources are stretched so thin. Thank you!”

“Supporting the needs of the pulmonary and critical care communities is what Boehringer Ingelheim has stood for throughout our company’s history and we are proud to stand with the ATS to make a critical difference to help slow the spread of COVID-19,” said Thomas Seck, MD, senior vice president, Medicine & Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. “This donation is one of several steps that our company is taking to provide assistance to healthcare professionals and patients facing this crisis.”

It is the ATS’s hope that this donation is the first in what will be a larger effort from industry to share their resources in helping to address the significant needs arising from the COVID-19 crisis.

For more information about making a donation to the ATS Crisis Fund, please contact the ATS Office of Development at dev@thoracic.org.